Fig. 4

EZH2 inhibitor (GSK126) preferentially inhibits the growth of UTX-deficient colorectal tumors. A Schematic model of the protocol used to induce colorectal tumors in C57BL/6 mice and for the administration of the EZH2 inhibitor GSK126. i.p., intraperitoneal. B and C Representative macroscopic (B) and H & E staining images (C) of large intestines from WT and Utx^−/y mice treated with vehicle or GSK126 (n = 7, respectively). Tumors were surrounded by dotted lines in representative images of H&E staining. Scale bar in (B), 5000 μm. Scale bar in (C), 200 μm. D Tumor number and load from large intestines of experimental mice (n = 7/group, respectively). E Representative IHC staining of H3K27me3 expression in colorectal tumors from WT and Utx^−/y mice treated with vehicle or GSK126. Scale bar, 20 μm. F IB analysis of WCL from three human primary CRC organoids. G Dose–response curves of organoids treated with GSK126 (n = 3). Data information: In (D and G), data are presented as mean ± SEM (one-way ANOVA with Dunnett’s multiple comparisons test). ns, non-significance, ^*P < 0.05, ^**P < 0.01